Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Interim Management Statement

10 May 2010 07:00

RNS Number : 5791L
Tarsus Group PLC
10 May 2010
 



 

 

 

TARSUS GROUP plc

 

Interim Management Statement

 

Tarsus Group Plc ("Tarsus" or "the Group"), the international business-to-business media group, is today publishing its Interim Management Statement relating to the period from the publication of its Preliminary Results on 8 March 2010 to 9 May 2010.

 

Trading Performance

 

Trading for the period has been in line with the Board's expectations. A summary of major developments includes:

 

§ US - continued recovery & momentum

 

The Medical division continues to gain momentum. The April Orlando event produced revenues well ahead of last year, driven by very strong growth from its education programmes. Exhibition and conference revenues also grew for the first time in 18 months.

 

§ France - management action retains margins within expectations

 

A number of small exhibitions have taken place in France since 8 March. As expected, the declining revenue trends experienced in the second half of 2009 have continued into the first half of 2010. Strong cost management has resulted in margins remaining within our expectations.

 

§ Emerging Markets

 

No material events have taken place since 8 March.

 

Financial Position

 

There have been no significant changes to the financial position of the Group since the publication of the Preliminary Results on 8 March 2010.

 

Outlook

 

At our preliminary results at the start of March we announced the launch of "Project 50/13" to accelerate our scale in Emerging Markets. Our business infrastructure in the region is now established and Tarsus has a much improved platform within Asia and the Middle East from which to continue to drive strong growth.

 

As in previous years, the Group's revenues remain heavily second-half weighted and, overall, forward bookings remain at a similar level to 2009.

 

The French portfolio is weighted towards the 4th quarter of the year and we are now seeing signs of stabilisation in that market, with forward bookings for 4th quarter events at similar levels to last year. Given the current economic outlook for Europe, we continue to remain cautious.

 

US sales are strong and ahead of 2009, driven mainly by our Off-Price (discount clothing) and Medical divisions. Labelexpo America's sales are marginally behind the previous edition, owing to smaller exhibitors booking later in the cycle.

 

In the Emerging Markets division, the Group's largest event this year is MEBA (business aviation) which takes place in Dubai for which forward bookings are well ahead of the previous cycle.

 

Our view of trading for 2010 is unchanged with long term exhibition trends intact. The recovery in the US economy is benefiting our business in that market and we are seeing good growth prospects and opportunities in Emerging Markets. Our strong brands, diversified portfolio of market leading events and increased focus on Emerging Markets leave Tarsus well positioned for the future.

 

Tarsus Group plc:

 

Douglas Emslie, Group Managing Director 020 8846 2700

Ashley Milton, Group Finance Director 020 8846 2700

 

Media:

 

Madano Partnership

Matthew Moth 020 7593 4000

 

Investors/Analysts:

 

IRfocus

Neville Harris 020 7593 4015

 

Scott Harris

Stephen Scott, Jeremy Wiseman 020 7653 0030

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSKKODKABKDOPK
Date   Source Headline
8th Dec 20164:35 pmRNSHolding(s) in Company
8th Dec 20164:33 pmRNSHolding(s) in Company
8th Dec 20164:31 pmRNSHolding(s) in Company
8th Dec 20164:29 pmRNSHolding(s) in Company
8th Dec 20167:00 amRNSCompletion of Acquisition
7th Dec 20169:00 amRNSAdmission of Placing Shares
5th Dec 201612:30 pmRNSCompletion of Placing
5th Dec 20167:00 amRNSProposed Placing and Acquisition
1st Dec 201610:46 amRNSTotal Voting Rights
22nd Nov 20167:00 amRNSCapital Markets Event and Trading Update
9th Nov 20163:19 pmRNSBlock listing Interim Review
31st Oct 20169:52 amRNSTotal Voting Rights
13th Oct 20167:24 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSTrading Update
30th Sep 20169:53 amRNSTotal Voting Rights and Capital
1st Sep 201612:09 pmRNSTotal Voting Rights
15th Aug 20165:28 pmRNSInterim financial statements
9th Aug 20166:11 pmRNSHolding(s) in Company
29th Jul 201612:10 pmRNSTotal Voting Rights and Capital
27th Jul 20167:00 amRNSHalf-year Report
11th Jul 20161:30 pmRNSApplication for Admission
5th Jul 20161:12 pmRNSHolding(s) in Company
30th Jun 201612:28 pmRNSTotal Voting Rights
21st Jun 20164:42 pmRNSDirector/PDMR Shareholding
20th Jun 20164:00 pmRNSResult of AGM
7th Jun 20161:15 pmRNSDirector/PDMR Shareholding
3rd Jun 20162:58 pmRNSScrip Dividend Circular (the "Circular")
31st May 201611:59 amRNSTotal Voting Rights and Capital
17th May 20163:08 pmRNSNotice of 2016 Annual General Meeting
17th May 20167:00 amRNSTrading Update
11th May 20167:00 amRNSDirector/PDMR Shareholding
9th May 20163:43 pmRNSBlock Listing Six Monthly Return
29th Apr 20164:14 pmRNSTotal Voting Rights
31st Mar 20162:25 pmRNSTotal Voting Rights
31st Mar 20162:24 pmRNSDirector/PDMR Shareholding
21st Mar 20163:11 pmRNS2015 Annual Report
8th Mar 20165:55 pmRNSDirector/PDMR Shareholding
3rd Mar 20164:47 pmRNSDirector/PDMR Shareholding
2nd Mar 20167:00 amRNSFinal Results
2nd Feb 20163:48 pmRNSTotal Voting Rights and Capital
25th Jan 20161:05 pmRNSApplication for Admission
12th Jan 20167:00 amRNSYear-end trading update
31st Dec 20159:25 amRNSTotal Voting Rights
14th Dec 20155:07 pmRNSScrip dividend circular
8th Dec 20157:00 amRNSCapital markets presentation
2nd Dec 20153:49 pmRNSDirector/PDMR Shareholding
30th Nov 20154:35 pmRNSTotal Voting Rights
11th Nov 201510:00 amRNSBlock Listing Six Monthly Return
30th Oct 20153:22 pmRNSDirector/PDMR Shareholding
30th Oct 20153:20 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.